Technical Data Sheet

InVivoMAb anti-mouse PD-1 (CD279)



Lot Specific Information

Lot Number:Lot Specific*Volume:Lot Specific*

Concentration: Lot Specific* (generally 4 to 11 mg/ml) *

Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Reported Applications:

Catalog Number: BE0033-2 Clone: J43

Isotype: Armenian Hamster IgG

Recommended Isotype Control(s): InVivoMAb polyclonal Armenian hamster IgG

Recommended Dilution Buffer: InVivoPure pH 6.5 Dilution Buffer

Immunogen: Syrian Hamster BKH cells transfected with mouse PD-1 cDNA

in vivo blocking of PD-1/PD-L signaling

in vitro PD-1 neutralization

Western blot PBS, pH 6.5

Formulation: Contains no stabilizers or preservatives

<2EU/mg (<0.002EU/µg)

Endotoxin: Vetermined by I AL gre

Determined by LAL gel clotting assay

Purity:

Determined by SDS-PAGE

Sterility: 0.2 µM filtered

Production: Purified from tissue culture supernatant in an animal free facility

Purification:Protein GRRID:AB_1107747Molecular Weight:150 kDa

Description

The J43 monoclonal antibody reacts with mouse PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the *Pdcd1* gene that belongs to the CD28 family of the immunoglobulin superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, *Pdcd1* mRNA is expressed in developing B lymphocytes during the pro-B-cell stage. PD-1's structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease in mice as PD-1 knockout animals show dilated cardiomyopathy, splenomegaly, and loss of peripheral tolerance. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In mouse models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. For these reasons anti-PD-1 mediated immunotherapies are currently being explored as cancer treatments. The J43 antibody has been shown to block the binding of both mouse PD-L1-Ig and mouse PD-L2-Ig to PD-1.

Shelf-life and Storage

Store at the stock concentration at 4°C. Do not freeze.

All Bio X Cell antibodies have a guaranteed shelf-life of one year from the date of customer receipt when stored as recommended. It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at bxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

Bio X Cell, Inc.

bxcell.com 1.866.787.3444

customerservice@bxcell.com


Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

For a complete list of references, visit https://bxcell.com/product/m-cd279/#references or scan the QR code below.



Binding Validation

Western blot data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, email technicalservice@bxcell.com.



Bio X Cell, Inc.